论文信息 - The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial - 字舞流文

The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial

P. Zinzani | O. O’Connor | Sung-Soo Yoon | J. Chavez | N. Goldschmidt | F. Cavallo | E. Hawkes | Ľ. Drgoňa | F. Samaniego | N. Fowler | T. Wróbel | I. Levi | P. Sportelli | H. Miskin | G. Fonseca | S. Yoon